Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: Prevention of flare progression. A randomized controlled trial

British Journal of Dermatology

Volumn 158, Issue 5, 2008, Pages 1083-1093

  Gollnick, H ^a   Kaufmann, R ^b   Stough, D ^c   Heikkila, H ^d   Andriano, K ^e   Grinienko, A ^e   Jimenez, P ^e  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Burke Pharmaceutical Research Inc   (United States)

^d HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA   (Finland)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atopic dermatitis; Eczema; Elidel ; Flare prevention; Pimecrolimus cream 1 ; Randomized controlled trial

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; DIFLUPREDNATE; EMOLLIENT AGENT; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PIMECROLIMUS; PREDNICARBATE;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC RHINITIS; ALLERGY; APPLICATION SITE BURNING; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BACKACHE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; ECZEMA; FEMALE; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; INFLUENZA; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SORE THROAT; SYMPTOM; TOOTH PAIN; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TACROLIMUS;

EID: 42049092566     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08484.x     Document Type: Article

References (60)

1. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 60.
2. Leung DY, Boguniewicz M, Howell MD et al. New insight into atopic dermatitis. J Clin Invest 2004 113 : 651 7.
3. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? who pays? J Am Acad Dermatol 1993 28 : 699 703.
4. Ellis CN, Drake LA, Prendergast MM et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002 46 : 361 70.
5. Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol 2001 45 : S64 6.
6. Paller AS, McAlister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila) 2002 41 : 323 32.
7. Schiffner R, Schiffner-Rohe J, Landthaler M et al. Treatment of atopic dermatitis and impact on quality of life. A review with emphasis on topical non-corticosteroids. Pharmacoeconomics 2003 21 : 159 79.
8. Bender BG, Leung SB, Leung DY. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J Allergy Clin Immunol 2003 111 : 598 602.
9. Przybilla B, Eberlein-Konig B, Rueff F. Practical management of atopic eczema. Lancet 1994 343 : 1342 6.
10. Williams HC. Do topical steroids reduce relapses in adults with atopic dermatitis? Arch Dermatol 1999 135 : 1530 1.
11. Leung DYM. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000 105 : 860 76.
12. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 2003 112 : S140 50.
13. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments of atopic eczema. Health Technol Assess 2000 4 : 1 191.
14. Hanifin JM, Cooper KD, Ho VC et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol 2004 50 : 391 404.
15. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila) 2000 39 : 1 14.
16. Hill CJ, Rosenberg A Jr. Adverse effects from topical corticosteroids. Cutis 1978 21 : 624 8.
17. Stoppolino G, Prisco F, Santinelli R et al. Potential hazards of topical steroid therapy. Am J Dis Child 1983 137 : 1130 1.
18. Lewis-Jones S. Atopic dermatitis in childhood. Hosp Med 2001 62 : 136 43.
19. Queille C, Pommarede R, Saurat JH. Efficacy versus systemic side effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984 1 : 246 53.
20. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986 115 : 475 84.
21. Turpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol 1988 118 : 517 22.
22. Turpeinen M, Lehtokoski-Lehtiniemi E, Leisti S, Salo OP. Percutaneous absorption of hydrocortisone during and after the acute phase of dermatitis in children. Pediatr Dermatol 1988 5 : 276 9.
23. Queille-Roussel C, Paul C, Duteil C et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double blind controlled study. Br J Dermatol 2001 144 : 507 13.
24. Haapasaari KM, Risteli J, Koivukangas V, Oikarinen A. Comparison of the effect of hydrocortisone, hydrocortisone-17-butyrate and betamethasone on collagen synthesis in human skin in vivo. Acta Derm Venereol (Stockh) 1995 75 : 269 71.
25. Haapasaari KM, Risteli J, Karvonen J, Oikarinen A. Effect of hydrocortisone, methylprednisolone acetonate and mometasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol 1997 10 : 261 4.
26. Oikarinen A, Haapasaari KM, Sutinen M, Tasanen K. The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. Br J Dermatol 1998 139 : 1106 10.
27. Sheu HM, Lee JYY, Chai CY, Kuo K. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 1997 136 : 884 90.
28. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 2001 7 : 73 7.
29. Kao JS, Fluhr JW, Man MQ et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003 120 : 456 64.
30. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006 54 : 1 15.
31. du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol 1976 112 : 1245 8.
32. Kligman AM, Frosch PJ. Steroid addiction. Int J Dermatol 1979 18 : 23 31.
33. Zheng PS, Lavker RM, Lehmann P et al. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol 1984 82 : 345 52.
34. Singh G, Singh PK. Tachyphylaxis to topical steroids measured by histamine-induced wheal suppression. Int J Dermatol 1986 25 : 324 6.
35. Fischer G. Compliance problems in paediatric atopic eczema. Australas J Dermatol 1996 37 (Suppl. 1 S10 13.
36. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000 142 : 931 6.
37. Fukaya M. Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology 2000 201 : 242 5.
38. Lucky AW, Leach AD, Laskarzewski P, Wenk H. The use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997 14 : 321 4.
39. Graham-Brown RAC, Grassberger M. Pimecrolimus: a review of preclinical and clinical data. Int J Clin Pract 2003 57 : 319 27.
40. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol 2004 13 : 721 30.
41. Meurer M, Fölster-Holst R, Wozel G et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002 205 : 271 7.
42. Luger TA, Lahfa M, Fölster-Holst R et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004 15 : 169 78.
43. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002 46 : 495 504.
44. Kapp A, Papp K, Bingham A et al. Flare Reduction in Eczema with Elidel (infants) multicentre investigator study group: long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002 110 : 277 84.
45. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 110 : e2.
46. Whalley D, Huels J, McKenna SP, van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002 110 : 1133 6.
47. Ho VC, Gupta A, Kaufmann R et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003 142 : 155 62.
48. Kaufmann R, Fölster-Holst R, Hoger P et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004 114 : 1183 8.
49. Papp KA, Werfel T, Fölster-Holst R et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005 52 : 240 6.
50. Harper J, Green A, Scott G et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 144 : 781 7.
51. Harper J, Lakhanpaul M, Wahn U et al. Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic dermatitis. J Eur Acad Dermatol Venereol 2001 15 (Suppl. 2 109 10 (Abstract).
52. Lakhanpaul M, Davies T, Allen BR, Schneider D. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol 2006 15 : 138 41.
53. Allen BR, Lakhanpaul M, Morris A et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 88 : 969 73.
54. Papp KA, Breuer K, Meurer M et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005 52 : 247 53.
55. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005 211 : 174 87.
56. U.S. Food and Drug Administration. FDA News. FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic. 2006. Available at: http://www.fda.gov/bbs/topics/news/2006/ NEW01299.html (last accessed 7 January 2008).
57. Kaplan EL, Meier P. Non-parametric estimation from incomplete samples. J Am Stat Assoc 1958 36 : 457 81.
58. Eichenfield LF, Lucky AW, Langley RGB et al. Use of pimecrolimus cream 1% (Elidel®) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. Int J Dermatol 2005 44 : 70 5.
59. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002 147 : 528 37.
60. Gould AL. A new approach to the analysis of clinical drug trials with withdrawals. Biometrics 1980 36 : 721 7.